Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag Switching Study in Chronic ITP
NCT04638829Phase 4Completed
- Sponsor
- Sobi
- Start
- Mar 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of avatrombopag in immune thrombocytopenia (ITP), sponsored by Sobi. Started Mar 2021; status: completed.
02
Drugs
avatrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04638829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638829.